Ding, J. W., Ning, Q., Liu, M. F., Lai, A., Peltekian, K., Fung, L., Holloway, C., Yeger, H., Phillips, M. J., & Levy, G. A. (1998). Expression of the fgl2 and its protein product (prothrombinase) in tissues during murine Hepatitis Virus Strain-3 (MHV-3) infection. Advances in Experimental Medicine and Biology, 440, 609-618. https://doi.org/10.1007/978-1-4615-5331-1_79
Expression of the fgl2 and its protein product (prothrombinase) in tissues during murine Hepatitis Virus Strain-3 (MHV-3) infection. / Ding, J. W.; Ning, Q.; Liu, M. F. et al.
In:
Advances in Experimental Medicine and Biology, Vol. 440, 1998, p. 609-618.
Research output: Contribution to journal › Article › peer-review
Ding, JW, Ning, Q, Liu, MF, Lai, A, Peltekian, K, Fung, L, Holloway, C, Yeger, H, Phillips, MJ & Levy, GA 1998, 'Expression of the fgl2 and its protein product (prothrombinase) in tissues during murine Hepatitis Virus Strain-3 (MHV-3) infection', Advances in Experimental Medicine and Biology, vol. 440, pp. 609-618. https://doi.org/10.1007/978-1-4615-5331-1_79
Ding JW, Ning Q, Liu MF, Lai A, Peltekian K, Fung L et al. Expression of the fgl2 and its protein product (prothrombinase) in tissues during murine Hepatitis Virus Strain-3 (MHV-3) infection. Advances in Experimental Medicine and Biology. 1998;440:609-618. doi: 10.1007/978-1-4615-5331-1_79
Ding, J. W. ; Ning, Q. ; Liu, M. F. et al. / Expression of the fgl2 and its protein product (prothrombinase) in tissues during murine Hepatitis Virus Strain-3 (MHV-3) infection. In: Advances in Experimental Medicine and Biology. 1998 ; Vol. 440. pp. 609-618.
@article{7e94b65e2f544e4db50b3be36f37a39a,
title = "Expression of the fgl2 and its protein product (prothrombinase) in tissues during murine Hepatitis Virus Strain-3 (MHV-3) infection",
abstract = "Murine Hepatitis Virus Strain 3 (MHV-3) produces fulminant hepatitis with 80-90% mortality in Balb/cJ mice. Previous studies in our laboratory have shown that peritoneal macrophages from MHV-3 infected mice produce a procoagulant (PCA) which has the ability to cleave prothrombin to thrombin (prothrombinase) encoded by the gene fgl2 located on chromosome 5. PCA accounts for sinusoidal thrombosis and hepatic necrosis and the necrosis and mortality can be prevented by treatment of animals with a monoclonal antibody to PCA. These present studies were designed to examine the expression of this gene (mRNA by Northern analysis and in situ hybridization) and the gene product PCA (immunochemistry) in tissues recovered from MHV-3 infected Balb/cJ mice in an attempt to explain the liver specific nature of MHV-3 disease. Fgl2 gene expression was detected as early as 8 hours after MHV-3 infection which persisted to 48 hours in the liver, spleen and lungs whereas no gene expression was seen in the brain or kidneys despite the fact that equivalent viral titers were detected in all tissues at all times. In the liver, fgl2 gene expression was confined to endothelial and Kupffer cells with no expression in hepatocytes. Immunochemistry localized the PCA protein to Kupffer cells and endothelial cells and necrotic foci within the liver. No PCA protein was detected by immunochemistry in any other tissues at any time during the course of MHV-3 infection. These results explain the liver specific nature (fulminant hepatitis) of MHV-3 infection and provides further evidence for the role of PCA in the pathogenesis of fulminant hepatitis. MHV-3 induces selective transcription of the gene fgl2 and only hepatic reticuloendothelial cells produce functional protein (PCA) which is known to account for fulminant hepatic failure produced by MHV-3.",
author = "Ding, {J. W.} and Q. Ning and Liu, {M. F.} and A. Lai and K. Peltekian and L. Fung and C. Holloway and H. Yeger and Phillips, {M. J.} and Levy, {G. A.}",
year = "1998",
doi = "10.1007/978-1-4615-5331-1_79",
language = "English",
volume = "440",
pages = "609--618",
journal = "Advances in Experimental Medicine and Biology",
issn = "0065-2598",
publisher = "Springer New York",
}
TY - JOUR
T1 - Expression of the fgl2 and its protein product (prothrombinase) in tissues during murine Hepatitis Virus Strain-3 (MHV-3) infection
AU - Ding, J. W.
AU - Ning, Q.
AU - Liu, M. F.
AU - Lai, A.
AU - Peltekian, K.
AU - Fung, L.
AU - Holloway, C.
AU - Yeger, H.
AU - Phillips, M. J.
AU - Levy, G. A.
PY - 1998
Y1 - 1998
N2 - Murine Hepatitis Virus Strain 3 (MHV-3) produces fulminant hepatitis with 80-90% mortality in Balb/cJ mice. Previous studies in our laboratory have shown that peritoneal macrophages from MHV-3 infected mice produce a procoagulant (PCA) which has the ability to cleave prothrombin to thrombin (prothrombinase) encoded by the gene fgl2 located on chromosome 5. PCA accounts for sinusoidal thrombosis and hepatic necrosis and the necrosis and mortality can be prevented by treatment of animals with a monoclonal antibody to PCA. These present studies were designed to examine the expression of this gene (mRNA by Northern analysis and in situ hybridization) and the gene product PCA (immunochemistry) in tissues recovered from MHV-3 infected Balb/cJ mice in an attempt to explain the liver specific nature of MHV-3 disease. Fgl2 gene expression was detected as early as 8 hours after MHV-3 infection which persisted to 48 hours in the liver, spleen and lungs whereas no gene expression was seen in the brain or kidneys despite the fact that equivalent viral titers were detected in all tissues at all times. In the liver, fgl2 gene expression was confined to endothelial and Kupffer cells with no expression in hepatocytes. Immunochemistry localized the PCA protein to Kupffer cells and endothelial cells and necrotic foci within the liver. No PCA protein was detected by immunochemistry in any other tissues at any time during the course of MHV-3 infection. These results explain the liver specific nature (fulminant hepatitis) of MHV-3 infection and provides further evidence for the role of PCA in the pathogenesis of fulminant hepatitis. MHV-3 induces selective transcription of the gene fgl2 and only hepatic reticuloendothelial cells produce functional protein (PCA) which is known to account for fulminant hepatic failure produced by MHV-3.
AB - Murine Hepatitis Virus Strain 3 (MHV-3) produces fulminant hepatitis with 80-90% mortality in Balb/cJ mice. Previous studies in our laboratory have shown that peritoneal macrophages from MHV-3 infected mice produce a procoagulant (PCA) which has the ability to cleave prothrombin to thrombin (prothrombinase) encoded by the gene fgl2 located on chromosome 5. PCA accounts for sinusoidal thrombosis and hepatic necrosis and the necrosis and mortality can be prevented by treatment of animals with a monoclonal antibody to PCA. These present studies were designed to examine the expression of this gene (mRNA by Northern analysis and in situ hybridization) and the gene product PCA (immunochemistry) in tissues recovered from MHV-3 infected Balb/cJ mice in an attempt to explain the liver specific nature of MHV-3 disease. Fgl2 gene expression was detected as early as 8 hours after MHV-3 infection which persisted to 48 hours in the liver, spleen and lungs whereas no gene expression was seen in the brain or kidneys despite the fact that equivalent viral titers were detected in all tissues at all times. In the liver, fgl2 gene expression was confined to endothelial and Kupffer cells with no expression in hepatocytes. Immunochemistry localized the PCA protein to Kupffer cells and endothelial cells and necrotic foci within the liver. No PCA protein was detected by immunochemistry in any other tissues at any time during the course of MHV-3 infection. These results explain the liver specific nature (fulminant hepatitis) of MHV-3 infection and provides further evidence for the role of PCA in the pathogenesis of fulminant hepatitis. MHV-3 induces selective transcription of the gene fgl2 and only hepatic reticuloendothelial cells produce functional protein (PCA) which is known to account for fulminant hepatic failure produced by MHV-3.
UR - http://www.scopus.com/inward/record.url?scp=0031721786&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0031721786&partnerID=8YFLogxK
U2 - 10.1007/978-1-4615-5331-1_79
DO - 10.1007/978-1-4615-5331-1_79
M3 - Article
C2 - 9782336
AN - SCOPUS:0031721786
SN - 0065-2598
VL - 440
SP - 609
EP - 618
JO - Advances in Experimental Medicine and Biology
JF - Advances in Experimental Medicine and Biology
ER -